Cover Image
市場調查報告書

Bioheart, Inc.的產品平台分析

Bioheart, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251747
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
Bioheart, Inc.的產品平台分析 Bioheart, Inc. - Product Pipeline Review - 2015
出版日期: 2015年06月24日 內容資訊: 英文 37 Pages
簡介

Bioheart, Inc.,是著重開發心血管疾病及其相關疾病治療的細胞技術的生物醫藥品企業。

本報告提供Bioheart, Inc.的產品開發平台的現狀及各開發階段比較分析、藥物簡介、開發平台的分析與最新趨勢、現在暫停中的計劃等資訊。

Bioheart, Inc.的基本資料

Bioheart, Inc.概要

  • 主要資訊
  • 企業資料

Bioheart, Inc.:R&D概要

  • 主要的治療範圍

Bioheart, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式

Bioheart, Inc.:開發中產品概況

  • 後期開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
  • IND/CTA申請的產品/聯合治療模式
    • 前臨床階段的產品/聯合治療模式

Bioheart, Inc.:開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

Bioheart, Inc.:藥物簡介

  • MyoCell
  • AdipoCell
  • AdipoCell + MyoCell
  • MyoCell SDF-1

Bioheart, Inc.:開發平台分析

  • 各給藥途徑
  • 各分子類型

Bioheart, Inc.:最近的開發平台趨勢

Bioheart, Inc.:暫停中的計劃

Bioheart, Inc.:企業發表

Bioheart, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07240CDB

Summary

Global Markets Direct's, 'Bioheart, Inc. - Product Pipeline Review - 2015', provides an overview of the Bioheart, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Bioheart, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Bioheart, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Bioheart, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Bioheart, Inc.'s pipeline products

Reasons to buy

  • Evaluate Bioheart, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Bioheart, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Bioheart, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Bioheart, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bioheart, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Bioheart, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Bioheart, Inc. Snapshot
    • Bioheart, Inc. Overview
    • Key Information
    • Key Facts
  • Bioheart, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Bioheart, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Bioheart, Inc. - Pipeline Products Glance
    • Bioheart, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Bioheart, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Bioheart, Inc. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
    • Bioheart, Inc. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Bioheart, Inc. - Drug Profiles
    • MyoCell
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AdipoCell
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AdipoCell + MyoCell
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MyoCell SDF-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Bioheart, Inc. - Pipeline Analysis
    • Bioheart, Inc. - Pipeline Products by Route of Administration
    • Bioheart, Inc. - Pipeline Products by Molecule Type
  • Bioheart, Inc. - Recent Pipeline Updates
  • Bioheart, Inc. - Dormant Projects
  • Bioheart, Inc. - Company Statement
  • Bioheart, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Bioheart, Inc., Key Information
  • Bioheart, Inc., Key Facts
  • Bioheart, Inc. - Pipeline by Indication, 2015
  • Bioheart, Inc. - Pipeline by Stage of Development, 2015
  • Bioheart, Inc. - Monotherapy Products in Pipeline, 2015
  • Bioheart, Inc. - Combination Treatment Modalities in Pipeline, 2015
  • Bioheart, Inc. - Phase III, 2015
  • Bioheart, Inc. - Phase II, 2015
  • Bioheart, Inc. - Phase I, 2015
  • Bioheart, Inc. - IND/CTA Filed, 2015
  • Bioheart, Inc. - Preclinical, 2015
  • Bioheart, Inc. - Unknown, 2015
  • Bioheart, Inc. - Pipeline by Route of Administration, 2015
  • Bioheart, Inc. - Pipeline by Molecule Type, 2015
  • Bioheart, Inc. - Recent Pipeline Updates, 2015
  • Bioheart, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Bioheart, Inc. - Pipeline by Top 10 Indication, 2015
  • Bioheart, Inc. - Pipeline by Stage of Development, 2015
  • Bioheart, Inc. - Monotherapy Products in Pipeline, 2015
  • Bioheart, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Bioheart, Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top